Several pharmacological inhibitors of YAP signaling are currently being developed, most of them inhibiting the interaction of YAP1 with TEAD transcription factors, and their efficacy is being evaluated for other cancers, such as NF2 mutant mesothelioma (24). The gene discussed is YAP1; the disease is mesothelioma.